Matinas BioPharma (MTNB) Q3 2024 earnings summary

Executive summary

• Ceased all product development and implemented an 80% workforce reduction in October 2024 after failed negotiations for MAT2203 global rights, shifting focus to strategic alternatives including potential winddown or dissolution.

• MAT2203, the lead product candidate, was the primary focus prior to the cessation of R&D; all development activities have now stopped to conserve cash.

• Net loss for the nine months ended September 30, 2024 was $15.8 million, a decrease from $17.6 million in the prior year period.

• No revenue generated in 2024; prior year revenue of $1.1 million was from research collaborations.

• Substantial doubt exists about the ability to continue as a going concern due to insufficient cash to fund operations beyond the next twelve months.

Financial highlights

• Cash, cash equivalents, and marketable debt securities totaled $10.8 million as of September 30, 2024.

• Net cash used in operating activities was $12.4 million for the nine months ended September 30, 2024.

• Net proceeds of $9.2 million were raised in an April 2024 registered direct offering.

• Accumulated deficit reached $191.4 million as of September 30, 2024.

• Research and development expenses decreased to $9.1 million and general and administrative expenses to $7.1 million for the nine months ended September 30, 2024.

Outlook and guidance

• Expenses expected to be limited to supporting regulatory compliance and MAT2203 Compassionate/Expanded Use Access Program while strategic alternatives are evaluated.

• No expectation of resuming product development unless additional funding is secured.

• Substantial doubt remains about the ability to continue as a going concern without new financing.